PDS Planning Inc Buys 3,638 Shares of Haleon plc (NYSE:HLN)

PDS Planning Inc increased its stake in Haleon plc (NYSE:HLN) by 22.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,047 shares of the company’s stock after buying an additional 3,638 shares during the period. PDS Planning Inc’s holdings in Haleon were worth $191,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Sierra Ocean LLC bought a new position in shares of Haleon in the 4th quarter worth approximately $26,000. Versant Capital Management Inc grew its stake in Haleon by 2,029.1% in the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after purchasing an additional 3,348 shares during the period. Geneos Wealth Management Inc. bought a new position in Haleon in the fourth quarter worth $35,000. Toronto Dominion Bank lifted its position in Haleon by 3,470.0% during the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock valued at $38,000 after buying an additional 3,470 shares during the period. Finally, Spire Wealth Management bought a new stake in shares of Haleon during the 4th quarter valued at $39,000. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HLN has been the subject of a number of recent research reports. HSBC reissued a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. Morgan Stanley lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Haleon in a research note on Monday, March 3rd. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Finally, Hsbc Global Res cut Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Six research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Haleon has an average rating of “Hold” and an average target price of $10.95.

Haleon Price Performance

Shares of NYSE HLN opened at $10.38 on Thursday. The firm has a market cap of $46.97 billion, a P/E ratio of 30.51, a PEG ratio of 2.82 and a beta of 0.25. Haleon plc has a twelve month low of $7.99 and a twelve month high of $10.80. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The company has a 50 day moving average of $9.80 and a 200 day moving average of $9.88.

Haleon (NYSE:HLN) last posted its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The firm had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.38 billion. As a group, research analysts expect that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The business also recently declared a — dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be paid a $0.1166 dividend. The ex-dividend date of this dividend is Friday, April 25th. This is a positive change from Haleon’s previous — dividend of $0.05. This represents a dividend yield of 1.6%. Haleon’s payout ratio is currently 58.97%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.